| Name | Title | Contact Details |
|---|
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
Century Healthcare provides functional solutions to help employers meet the challenges of today`s complex healthcare environment. We are an organization committed to the design, implementation and administration of customized benefit plans for employers of all sizes throughout the U.S.
MDInfo is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OptiScan Biomedical Corp is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Incapital was founded in 1999 with the mission of providing securities firms and individual investors more efficient access to corporate bonds. While Incapital`s expertise in underwriting and distributing investment-grade corporate bonds remains a core competency, the firm now originates and distributes offerings across multiple asset classes. In addition to its broker-dealer and bank partners, Incapital now serves institutional investors and wealth managers. With over 150 employees in multiple offices in North America, the firm represents over 400 issuing entities and serves 800+ distribution partners. Incapital continues to provide market leadership with a growing range of product offerings, strong strategic partnerships and innovative technology.